Drugs and Devices

FDA approves Synribo for chronic myelogenous leukemia

On Oct. 26, the U.S. Food and Drug Administration (FDA) approved Synribo (omacetaxine mepesuccinate) for the treatment of adults with chronic myelogenous leukemia. Synribo blocks certain proteins that promote the development of cancerous cells. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares